We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Ontario, Canada-based AlphaRx has entered into a collaboration with PharmaSeed, headquartered in Israel, for the development of new drugs for the treatment of central nervous system (CNS) disorders such as stroke and multiple sclerosis.
Swiss drugmaker Roche and the Cambodia Treatment Access Program (CTAP) have enrolled more than 1,000 men, women and children infected with HIV/AIDS to receive care and treatment free-of-charge in the country.
Japan-based Ube Industries and Santen Pharmaceutical have entered into an agreement to develop DE-104, a compound that inhibits the activity of Rho-kinase (ROCK).